AIMS: Anaemia is a co-morbidity frequently seen in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Its presence carries adverse prognostic effects. The effects of anaemia have not been extensively investigated in patients with preserved or only mildly reduced LVEF. We sought to investigate prevalence and incidence of anaemia in patients with HF irrespective of whether reduced or preserved ejection fraction are present. In addition, we sought to study the effects of nebivolol on the development of anaemia. METHODS AND RESULTS: We analysed data from 2069 patients randomized tonebivolol or placeboin the SENIORS study, 391 (10.0%) of whom were anaemic. Anaemia was similarly common in patients with LVEF≤35% and those with LVEF>35% (19.0 vs. 18.7%, P= 0.89). Anaemic patients were older, had lower diastolic blood pressure, and worse kidney function (all P< 0.05). No difference was found between patients on nebivolol or placebo with regard to the presence of anaemia. A total of 348 (16.8%) patients died during follow-up. The combined primary endpoint of all-cause mortality and cardiovascular hospital admission was reached by 687 (33.2%) patients during follow-up, 164 (23.4%) of whom were anaemic. Anaemic patients had a higher risk of reaching a primary endpoint than non-anaemics [LVEF≤35%: hazard ratio (HR) 1.47, 95% confidence interval (CI) 1.18-1.82, P< 0.001; LVEF>35%: HR 1.47, 95% CI 1.09-2.00, P= 0.012]. After multivariable adjustment, haemoglobin remained an independent predictor of the primary outcome in this cohort of patients (HR 0.94 per 1 g/dL increase, 95% CI 0.89-0.99, P= 0.017). CONCLUSIONS:Anaemia is an independent predictor of death or hospitalization for cardiovascular reasons among elderly patients with chronic HF and reduced or preserved/mildly reduced LVEF. Nebivolol does not affect haemoglobin values during follow-up.
RCT Entities:
AIMS: Anaemia is a co-morbidity frequently seen in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Its presence carries adverse prognostic effects. The effects of anaemia have not been extensively investigated in patients with preserved or only mildly reduced LVEF. We sought to investigate prevalence and incidence of anaemia in patients with HF irrespective of whether reduced or preserved ejection fraction are present. In addition, we sought to study the effects of nebivolol on the development of anaemia. METHODS AND RESULTS: We analysed data from 2069 patients randomized to nebivolol or placebo in the SENIORS study, 391 (10.0%) of whom were anaemic. Anaemia was similarly common in patients with LVEF≤35% and those with LVEF>35% (19.0 vs. 18.7%, P= 0.89). Anaemic patients were older, had lower diastolic blood pressure, and worse kidney function (all P< 0.05). No difference was found between patients on nebivolol or placebo with regard to the presence of anaemia. A total of 348 (16.8%) patients died during follow-up. The combined primary endpoint of all-cause mortality and cardiovascular hospital admission was reached by 687 (33.2%) patients during follow-up, 164 (23.4%) of whom were anaemic. Anaemic patients had a higher risk of reaching a primary endpoint than non-anaemics [LVEF≤35%: hazard ratio (HR) 1.47, 95% confidence interval (CI) 1.18-1.82, P< 0.001; LVEF>35%: HR 1.47, 95% CI 1.09-2.00, P= 0.012]. After multivariable adjustment, haemoglobin remained an independent predictor of the primary outcome in this cohort of patients (HR 0.94 per 1 g/dL increase, 95% CI 0.89-0.99, P= 0.017). CONCLUSIONS:Anaemia is an independent predictor of death or hospitalization for cardiovascular reasons among elderly patients with chronic HF and reduced or preserved/mildly reduced LVEF. Nebivolol does not affect haemoglobin values during follow-up.
Authors: Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2014-11-24 Impact factor: 24.094
Authors: C Berry; K K Poppe; G D Gamble; N J Earle; J A Ezekowitz; I B Squire; J J V McMurray; F A McAlister; M Komajda; K Swedberg; A P Maggioni; A Ahmed; G A Whalley; R N Doughty; L Tarantini Journal: QJM Date: 2015-05-14
Authors: Peter A McCullough; Denise Barnard; Robert Clare; Stephen J Ellis; Jerome L Fleg; Gregg C Fonarow; Barry A Franklin; Ryan D Kilpatrick; Dalane W Kitzman; Christopher M O'Connor; Ileana L Piña; Udho Thadani; Vinay Thohan; David J Whellan Journal: Clin Cardiol Date: 2013-08-08 Impact factor: 2.882
Authors: Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling Journal: Nat Rev Nephrol Date: 2016-08-30 Impact factor: 28.314
Authors: Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske Journal: Eur Heart J Date: 2014-08-07 Impact factor: 29.983